Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCB01A in recurrent/metastatic head and neck cancer
NCT02488629Phase 2Terminated
- Sponsor
- SynCore Biotechnology
- Start
- Sep 2015
- Primary completion
- Dec 2017
- Modality
- Allosteric Modulators, Orthosteric Ligands, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SCB01A in head and neck squamous cell carcinoma (HNSCC), sponsored by SynCore Biotechnology. Primary endpoint: Disease Control Rate at 9 weeks. Started Sep 2015; status: terminated.
02
Drugs
SCB01A
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02488629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02488629.